CD Bioparticles Announces Offering of Polylactides for Researchers

Top Quote CD Bioparticles introduces a series of polylactides to support drug delivery research. End Quote
  • (1888PressRelease) December 24, 2021 - CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of polylactides to support drug delivery research, which are vinylically reactive for binding into radical chain synthesized polymers.

    Customers can choose polylactides products by functional groups, such as acid, 1,10-decadiol, acrylate, amine, butanol, ester, hydroxyl, maleimide, and thiol, with low/medium/high molecular weight and various other weight, such as 2,000 Da, and 1,000-5,000 Da. These new products such as Poly(D,L-lactide)-di-Acrylate, Poly(D,L-lactide)-di-Decanol, α-Amine-ω-Hydroxyl-Poly(L-Lactide), α-Amine-ω-Hydroxyl-Poly(L-Lactide), and Poly(D,L-lactic acid)-Glycerol initiated branched Polymer are available at CD Bioparticles.

    Specializing in a range of formulation and drug delivery technologies, CD Bioparticles offers a series of biodegradable polymers for research uses. These new polylactides are a new addition of the biodegradable polymers, and can help researchers solve problems such as limited options for the bio-conjugation between macromolecules and biomolecules, unpredictable or uncontrollable degradation rate of the drug-loading cargo, and limited options for material solidification which limits the choice of the materials for additive manufacturing precision medicine.

    "If you want to get rid of tedious chemical synthesis and purifications, or uncontrollable drug delivery profile, our biodegradable polymers can be a good choice for you to conduct drug delivery projects. CD Bioparticles has strong and broad expertise and over years of experience in the drug delivery field. We can be your trusted partner in drug delivery, particularly in formulating challenging compounds with liposomes, polymers and other novel nano-enabled delivery technologies." said Dr. Robin J. Watts, the scientific officer of R&D department of CD Bioparticles.

    CD Bioparticles works closely with customers and collaborators to find the drug delivery solution that best fits their needs and its experts support clients through all stages of the development process, from formulation development to preclinical trials. Offering high quality products, customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms, CD Bioparticles can help solve scientists' challenges like lack of functional groups for further modification/conjugation/crosslinking, or lack of cell-specific or tissue-specific targeting for nanomedicines.

    "We understand our customers requirements and we're strongly committed to meeting their goals by continuously expanding our product portfolio and providing more new products. The new polylactides offering will help CD Bioparticles meet increasing demand for quality laboratory and biodegradable polymers products. Polylactides will be an ideal tool for scientists to proceed their studies." added Dr. Robin J. Watts.

    For more detailed information on polylactides or any other biodegradable polymers, please visit CD Bioparticles at

    About CD Bioparticles
    CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems. It specializes in a range of formulation and drug delivery technologies, from conventional liposomes, PEGylated liposomes for drug delivery to polymer microspheres and nanoparticles for enhanced drug delivery. It provides contract services of drug delivery formulation developments for basic research, formulation feasibility studies, process development and scale-up, formulation characterization, analytical and nonclinical services.

  • FB Icon Twitter Icon In-Icon
Contact Information